• Practical Guide: Benzyl-activated Streptavidin Magnetic Bead

  2026-04-23

  Benzyl-activated Streptavidin Magnetic Beads (SKU: K1301) address rapid, high-specificity capture of biotinylated molecules in purification, immunoprecipitation, and protein interaction workflows. The product is best suited for researchers requiring minimal nonspecific binding and reproducible results in molecular biology or biochemical assays. Its application is limited where non-biotin-based capture or extreme pH conditions are required.

• Strategic Deployment of BV6 IAP Antagonist in Translational

  2026-04-22

  This thought-leadership article explores the mechanistic underpinnings and translational strategy behind deploying BV6, a selective IAP antagonist, in apoptosis-driven cancer and endometriosis research. By interweaving evidence from primary literature, best-practice workflow guidance, and recent discoveries in regulated cell death pathways, we position BV6 (APExBIO) as a pivotal tool for translational researchers aiming to overcome therapeutic resistance and enhance experimental fidelity. The piece uniquely bridges bench-side validation with forward-looking strategy, highlighting both the opportunities and boundaries of current IAP-targeted approaches.

• Thiazovivin for Stem Cell Survival and Reprogramming Workflo

  2026-04-22

  Thiazovivin is a small molecule ROCK inhibitor that addresses the challenges of low cell survival during human embryonic stem cell (hESC) passaging and inefficiencies in induced pluripotent stem cell (iPSC) generation. It should be used in research protocols requiring enhanced cell viability and reprogramming efficiency, but is not intended for diagnostic or clinical applications.

• Applied Workflows with ddATP: Sanger Sequencing to DNA Repai

  2026-04-21

  APExBIO’s ddATP (2',3'-dideoxyadenosine triphosphate) empowers precise DNA synthesis termination across Sanger sequencing, DNA repair, and viral replication studies. Discover stepwise protocols, troubleshooting strategies, and translational innovations rooted in recent oocyte DNA repair research.

• GPR30 in Spinal CCK+ Neurons: A Gatekeeper of Neuropathic Pa

  2026-04-21

  This study uncovers how GPR30, a membrane estrogen receptor, is selectively upregulated in spinal cholecystokinin-positive (CCK+) neurons during neuropathic pain and demonstrates that inhibiting GPR30 in these neurons reverses pain symptoms in mice. These findings clarify the molecular and circuit-level mechanisms of neuropathic pain, highlighting GPR30 as a promising target for future research and therapeutic intervention.

• Semi-Automated Screening of Fast-Dissociating Antibodies for

  2026-04-20

  Miyoshi et al. developed a semi-automated single-molecule microscopy platform to screen for fast-dissociating yet highly specific monoclonal antibodies directly from hybridoma cultures. Their approach enables rapid identification and application of such antibodies for advanced multiplex imaging and real-time protein dynamics research, including efficient detection of V5 epitope tag fusion proteins.

• Selective α-Hydroxy-β-Amino Acid Inhibitors of IRAP: Synthes

  2026-04-20

  This study introduces a highly selective, nanomolar inhibitor scaffold for insulin-regulated aminopeptidase (IRAP), leveraging α-hydroxy-β-amino acid derivatives of bestatin. The work advances synthetic peptide chemistry by demonstrating a robust, diastereo- and regioselective approach for scaffold functionalization, yielding inhibitors with notable potency and selectivity relevant for immunological and therapeutic research.

• Bedaquiline (SKU B3492): Reliable Solutions for TB & Cancer

  2026-04-19

  This article guides bench scientists through common challenges in cell viability, proliferation, and cytotoxicity assays using Bedaquiline (SKU B3492). Each scenario-driven Q&A block demonstrates how rigorous selection and validated usage of this diarylquinoline antibiotic from APExBIO optimize reproducibility, sensitivity, and mechanistic insight, especially in tuberculosis and cancer metabolism research.

• Paroxetine Does Not Alter Thiothixene Pharmacokinetics in Hu

  2026-04-18

  This study rigorously evaluated whether paroxetine, a potent CYP2D6 inhibitor, impacts the pharmacokinetics of thiothixene in healthy volunteers. The findings demonstrate that short-term paroxetine pretreatment does not significantly alter thiothixene clearance, clarifying the metabolic pathway for this typical antipsychotic agent and informing clinical and research co-administration strategies.

• Estradiol Benzoate: Mechanistic Power for Translational Impa

  2026-04-17

  This article provides translational researchers with mechanistic insights and strategic guidance on leveraging Estradiol Benzoate as a high-affinity estrogen receptor alpha agonist. By critically comparing existing resources and integrating evidence-based best practices, it outlines how Estradiol Benzoate from APExBIO advances estrogen receptor signaling research, delivers robust data integrity, and serves as a benchmark tool for hormone receptor assays and modeling. Visionary outlook and protocol recommendations are offered to empower rigorous, reproducible discovery.

• Isoprinosine in Immunotherapy: Protocols and Viral Inhibitio

  2026-04-16

  Unlock Isoprinosine's dual antiviral and immunomodulatory power for translational research. This article delivers stepwise protocols, real-world troubleshooting, and data-driven insights, leveraging the latest herpesvirus biology and APExBIO's research-grade quality.

• Thiazovivin: Protocols and QC for ROCK Inhibition in Stem Ce

  2026-04-15

  Thiazovivin is a high-purity ROCK inhibitor designed to enhance induced pluripotent stem cell generation and improve human embryonic stem cell survival after dissociation. It is best suited for workflows requiring reliable inhibition of the ROCK signaling pathway, but should not be used for diagnostic or therapeutic applications. Researchers should follow storage and handling parameters closely to ensure experimental reproducibility.

• Photothermal Therapy and CD47 Blockade in OSCC: Mechanistic

  2026-04-14

  This study demonstrates that combining photothermal therapy (PTT) with CD47 blockade enhances the anti-tumor immune response in oral squamous cell carcinoma (OSCC). By inducing calreticulin (CRT) exposure and remodeling the tumor extracellular matrix (ECM), the dual approach overcomes immune evasion and physical barriers, significantly improving macrophage-mediated tumor clearance.

• Atorvastatin: HMG-CoA Reductase Inhibitor in Disease Modelin

  2026-04-13

  Atorvastatin’s unique duality as a cholesterol biosynthesis inhibitor and modulator of ferroptosis expands its research utility far beyond lipid studies. This article delivers actionable workflows, troubleshooting guidance, and translational insights for vascular, metabolic, and oncology research leveraging APExBIO’s high-quality Atorvastatin reagent.

• NMDA (N-Methyl-D-aspartic acid): Advanced Insights for Model

  2026-04-12

  Explore the advanced role of NMDA (N-Methyl-D-aspartic acid) in excitotoxicity and neurodegenerative research. This article unpacks cutting-edge assay guidance, protocol nuances, and novel reference-backed insights for researchers using NMDA in CNS models.

16362 records 1/1091 page Next 12345 下5页 Last page